Nasus Pharma Ltd. Market Cap ($33.96 Million)
Market Cap & Net Worth: Nasus Pharma Ltd. (NSRX)
Nasus Pharma Ltd. market cap. Nasus Pharma Ltd. (NYSE MKT:NSRX) has a market capitalization of $33.96 Million ($33.96 Million) as of November 6, 2026. Listed on the NYSE MKT stock exchange, this USA-based company holds position #23107 globally and #5043 in its home market, demonstrating a -2.36% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Nasus Pharma Ltd.'s stock price $2.90 by its total outstanding shares 11710808 (11.71 Million). Also see Nasus Pharma Ltd. operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Nasus Pharma Ltd. Market Cap History (2025–2026)
Nasus Pharma Ltd. market cap history from 2025 to 2026. Data shows growth from $107.15 Million to $33.96 Million (0.00% CAGR). Check NSRX live share price for real-time trading data and today's change.
Nasus Pharma Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Nasus Pharma Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore NSRX net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of NSRX by Market Capitalization
Companies near Nasus Pharma Ltd. in the global market cap rankings as of November 6, 2026. Also see Nasus Pharma Ltd. asset portfolio for a full breakdown of the balance sheet.
Key companies related to Nasus Pharma Ltd. by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #12 globally with a market cap of $1.06 Trillion USD.
- Eli Lilly and Company (SA:LILY34): Ranked #19 globally with a market cap of $853.51 Billion USD ( R$4.35 Trillion BRL).
- Johnson & Johnson (NYSE:JNJ): Ranked #28 globally with a market cap of $574.95 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #42 globally with a market cap of $356.49 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #12 | Eli Lilly and Company | NYSE:LLY | $1.06 Trillion | $1364.73 |
| #19 | Eli Lilly and Company | SA:LILY34 | $853.51 Billion | R$153.70 |
| #28 | Johnson & Johnson | NYSE:JNJ | $574.95 Billion | $272.32 |
| #42 | AbbVie Inc | NYSE:ABBV | $356.49 Billion | $288.24 |
Market Capitalization of Nasus Pharma Ltd. (2025–2026)
Market capitalization of Nasus Pharma Ltd. from 2025 to today. Between 2025 and today, Nasus Pharma Ltd.'s market cap moved from $107.15 Million to $ 33.96 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $33.96 Million | -68.31% |
| 2025 | $107.15 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 6th, 2026 the market cap of Nasus Pharma Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $33.96 Million USD |
| MoneyControl | $33.96 Million USD |
| MarketWatch | $33.96 Million USD |
| marketcap.company | $33.96 Million USD |
| Reuters | $33.96 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Nasus Pharma Ltd.
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS00… Read more